Literature DB >> 31831303

Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C.

Chun-Han Cheng1, Chia-Ying Chu2, Huan-Lin Chen1, I-Tsung Lin1, Chia-Hsien Wu1, Yuan-Kai Lee1, Ping-Jen Hu1, Ming-Jong Bair3.   

Abstract

BACKGROUND: There are many laboratory indices to assess liver fibrosis. Aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) index have been used as well-known serum markers of liver fibrosis. With the increasing use of non-invasive fibrosis assessment, it is important to recognize the limitations of these tests. The factors influencing the diagnostic accuracy to evaluate liver fibrosis are not well-established. This study aimed to perform a subgroup analysis of the predictive ability of laboratory indices.
METHODS: Overall, 113 patients with chronic hepatitis C infection who underwent liver biopsy were retrospectively examined. The histological assessment of liver fibrosis was performed using the METAVIR scoring system, and the values of several laboratory tests were also evaluated on the same day. We categorized our study population by treatment status, body mass index (BMI), and age.
RESULTS: The two laboratory indices APRI and FIB-4 index could predict advanced (F3-4) liver fibrosis and cirrhosis (F4), with the area under the receiver operating characteristic curve (AUROC) > 0.8 and accuracy >70%. The AUROCs and accuracies were higher among patients with sustained virological response (SVR) than among those without SVR. A higher predictive ability was also observed among patients with BMI <25 kg/m2. Age did not appear to affect liver fibrosis predictability.
CONCLUSIONS: The laboratory indices APRI and FIB-4 index exhibit good diagnostic performance for determining advanced fibrosis and cirrhosis among patients with hepatitis C infection. The diagnostic accuracy appears better among patients with SVR and those with BMI <25 kg/m2.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Biopsy; Fibrosis; Hepatitis C; Histology

Mesh:

Substances:

Year:  2019        PMID: 31831303     DOI: 10.1016/j.jmii.2019.09.002

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  5 in total

1.  Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage.

Authors:  Tiangui Li; Peng Wang; Xiao Gong; Weelic Chong; Yang Hai; Chao You; Juan Kang; Fang Fang; Yu Zhang
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

2.  ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis.

Authors:  Handan Yarkan Tugsal; Selcen Yuksel; Gokhan Kabacam; Sami Evirgen; Kubra Akan; Filiz Akyuz; Mine Gulluoglu; Esra Erden; A Mithat Bozdayi; Kubilay Cinar; Ramazan Idilman; Cihan Yurdaydin; Sabahattin Kaymakoglu; Hakan Bozkaya
Journal:  Hepatol Forum       Date:  2021-01-08

Review 3.  Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.

Authors:  Seyed Mohammad Ali Hashemi; Marijn Thijssen; Seyed Younes Hosseini; Alijan Tabarraei; Mahmoud Reza Pourkarim; Jamal Sarvari
Journal:  Arch Virol       Date:  2021-05-02       Impact factor: 2.685

Review 4.  MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Authors:  Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón
Journal:  Front Med (Lausanne)       Date:  2022-01-13

5.  FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.

Authors:  Behnaz Amernia; Seyed Hamid Moosavy; Fatemeh Banookh; Ghazal Zoghi
Journal:  BMC Gastroenterol       Date:  2021-12-03       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.